Egrifta Sv (Tesamorelin Acetate) Patent Expiration, LOE Window & CMS Spending

Egrifta Sv (Tesamorelin Acetate) by Theratechnologi: Off-Patent Genericized (AB Competition), 0 AB generics, $41.8M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTheratechnologi
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$41.8M
2024 Medicare Part D Spend$37.1M
2024 Medicaid Spend$4.7M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 20.2% 2-yr change)